CD274 and neoplasm: PDL-1 expression, metastatic site, tumor mutational burden, tumor-infiltrating lymphocytes, and the gut microbiome have been implicated in influencing the efficacy of ICIs [10,11].The development of cirAEs may be just one aspect of developing more individualized treatment prognostications as more information regarding patient-specific factors becomes available for use in clinical practice.